Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML
December 03, 2021 01:00 ET
|
Molecular Partners
Research collaboration with leading acute myeloid leukemia (AML) experts, Professor Ochsenbein and Professor Riether from the Department of Medical Oncology, Inselspital, Bern University Hospital,...
Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro
November 30, 2021 01:00 ET
|
Molecular Partners
Ensovibep retains activity with regard to all relevant individual positions mutated in Omicron, the newly discovered viral variant of concernTesting on the full Omicron variant has initiated, with...
Molecular Partners Announces Presentation at the Evercore ISI 4th Annual HealthCONx Conference
November 24, 2021 01:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19
November 16, 2021 01:00 ET
|
Molecular Partners
Following the futility analysis, the independent Data and Safety Monitoring Board (DSMB) recommends that the recruitment of patients in the ensovibep arm of ACTIV-3 not continue in hospitalized...
Molecular Partners Announces First Patient Dosed with CD40 Therapeutic Candidate MP0317 in Phase 1 Clinical Trial
November 04, 2021 02:00 ET
|
Molecular Partners
Second immuno-oncology DARPin candidate to enter the clinic; combines immune stimulation with validated tumor-localizing technologyPreclinical data support potential to deliver tumor-localized immune...
Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum
October 28, 2021 01:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference
October 20, 2021 01:00 ET
|
Molecular Partners
Ensovibep is shown in vitro to maintain inhibition against all variants of concern known to dateThe Company is also presenting a Trial in Progress poster on the EMPATHY clinical trial at the...
Molecular Partners to Present at Upcoming Healthcare Investor Conferences
September 03, 2021 16:05 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein...
Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021
August 26, 2021 01:00 ET
|
Molecular Partners
-- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3 ...
Molecular Partners to Regain Global Rights to Abicipar
August 09, 2021 01:00 ET
|
Molecular Partners
Global rights to registrational-stage ophthalmology drug return to Molecular PartnersImprovements in manufacturing and formulation have been made and tested in pre-clinical models with the potential...